Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | HRH1 | P35367 | 2/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.72 |
| ▸ | DRD3 | P35462 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | HRH2 | P25021 | 1/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868968 | 1.00 | SLC6A4 (0.76) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL144543 | 0.93 | SLC6A4 (0.72) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL141945 | 0.93 | SLC6A4 (0.65) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL141623 | 0.91 | SLC6A4 (0.83) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL4169521 | 0.89 | SLC6A4 (0.76) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL144619 | 0.89 | SLC6A4 (0.72) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL12780358 | 0.87 | SLC6A4 (0.78) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2615213 | 0.87 | SLC6A4 (0.78) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL4169876 | 0.86 | SLC6A4 (0.76) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL13234952 | 0.86 | SLC6A4 (0.84) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896439-B2 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | LUNDBECK & CO AS H (DK) | 2014-10-15 | — | — | EP | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7834201-B2 | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7723533-B2 | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base | H. LUNDBECK A/S (DK) | 2010-05-25 | — | — | US | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| US-7560576-B2 | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base | H. LUNDBECK A/S (DK) | 2009-07-14 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| US-6750358-B2 | 5-BROMO OR 5-CHLORO1-(3-(DIMETHYLAMINO)PROPYL)-1-(4-FLUORO PHENYL)-1,3-DIHYDROISOBENZOFURAN REACTED WITH A CYANIDE SOURCE IN THE PRESENCE OF A NICKEL CATALYST; ANTIDEPRESSANTS | H. LUNDBECK A/S (DK) | 2004-06-15 | — | — | US | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004011450-A1 | PROCESS FOR THE PREPARATION OF 1-(3-DIMETHYLAMINOPROPYL) -1-(4-FLUOROPHENYL) -1,3-DIHYDROISOBENZOFURAN -5-CARBONITRILE | ORION CORPORATION FERMION (FI) | 2004-02-05 | — | — | WO | disclosed |
| US-6635773-B2 | Purification by selective extraction of citalopram or its impurities using organic solvents and water, and the process for preparing citalopram salts | ESTEVE QUIMICA, S.A. (ES) | 2003-10-21 | — | — | US | disclosed |
| US-20030144534-A1 | Process for preparing citalopram | ESTEVE QUIMICA, S.A (ES) | 2003-07-31 | — | — | US | disclosed |
| US-20020061925-A1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2002-05-23 | — | — | US | disclosed |
| EP-1105382-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2002-02-13 | — | — | EP | disclosed |
| EP-1105382-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011926-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-03-09 | — | — | WO | disclosed |
| US-4136193-A | ANTI-DEPRESSIVE SUBSTITUTED 1-DIMETHYLAMINOPROPYL-1-PHENYL PHTHALANS | KEFALAS A/S (DK) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144534-A1 | Process for preparing citalopram | MAOB, MAOA, CMA1 | SLC6A4 39/4885SLC6A2 43/4885HTR2C 180/4885 |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | IFNG, IL5, HAVCR2 | SLC6A4 4506/4885SLC6A2 4415/4885HTR2C 4200/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SLC6A4 3269/4885SLC6A2 3188/4885HTR2C 3397/4885 |
| US-20020061925-A1 | Method for the preparation of citalopram | TPH1, MAOB, CYP2C19 | SLC6A4 4/4885SLC6A2 52/4885HTR2C 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.